Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Tongeye Medical Technology (Ningbo) Co., Ltd., founded in October 2023, pioneers cell therapies for ophthalmic diseases. Our breakthrough iPSC-derived youthful RPE cell therapy for dry retinal degeneration shows superior efficacy in animal models versus existing treatments. Proprietary induction technology slashes differentiation time from 120-150 days to just 25 days, dramatically lowering costs and improving patient access. ...
Tongeye Medical Technology (Ningbo) Co., Ltd., founded in October 2023, pioneers cell therapies for ophthalmic diseases. Our breakthrough iPSC-derived youthful RPE cell therapy for dry retinal degeneration shows superior efficacy in animal models versus existing treatments. Proprietary induction technology slashes differentiation time from 120-150 days to just 25 days, dramatically lowering costs and improving patient access. Backed by angel funding, we're advancing multiple R&D pipelines to restore vision for millions globally.

List your booth number for exhibitions, ask us